| Identification | Back Directory | [Name]
Ibipinabant | [CAS]
464213-10-3 | [Synonyms]
SLV319
BMS 646256
ibipinabant
(S)-SLV 319
Ibipinabant Impurity 1 ((S)-SLV 319)
(4S)-5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide
(4S)-3-(4-Chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methyl-4-phenyl-1H-pyrazole-1-carboximidamide
1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N'-methyl-4-phenyl-, (4S)- | [Molecular Formula]
C23H20Cl2N4O2S | [MDL Number]
MFCD07370146 | [MOL File]
464213-10-3.mol | [Molecular Weight]
487.4 |
| Chemical Properties | Back Directory | [density ]
1.38 | [storage temp. ]
Store at -20°C | [solubility ]
≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | [form ]
crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(S)-SLV 319 is a potent, selective CB1 receptor antagonist. | [Biological Activity]
ki: 7.8 and 7,9 nm for cb1 and peripheral cannabinoid (cb2), respectively(s)-slv 319 is a cb1 receptor antagonist.it has been reported that central cannabinoid (cb1) receptor antagonists may have potential in the treatment of a variety of diseases including cognitive disorders, neuro-inflammatory disorders, obesity, septic shock, psychosis, addiction, as well as gastrointestinal disorders. | [in vitro]
previous study found that (s)-slv 319 was a potent and selective cb1 receptor antagonist with ki values of 7.8 and 7,9 nm for cb1 and cb2, respectively. in addition, (s)-slv 319 was found to be less lipophilic and thus more water soluble than other previously identified ligands of cb1 receptor [1]. | [in vivo]
previous animal study showed that in rats exposed to an ambient temperature of 22°c, a moderate dose of lps at 25 - 100 μg/kg could induce a fall in body temperature. such response was not affected by desensitization of intra-abdominal trpv1 receptors with resiniferatoxin at 20 μg/kg, by systemic trpv1 antagonism with capsazepine at 40 mg/kg, or by systemic cb2 receptor antagonism with sr144528 at 1.4 mg/kg. in contrast, cb1 receptor antagonism by slv319 at 15 mg/kg or rimonabant at 4.6 mg/kg was able to block lps caused hypothermia [2]. | [IC 50]
CB1: 7.8 nM (Ki); CB2: 7943 nM (Ki) | [References]
[1] j. h. m. lange, h. h. van stuivenberg, w. veerman, et al. novel 3,4-diarylpyrazolines as potent cannabinoid cb1 receptor antagonists with lower lipophilicity. bioorganic & medicinal chemistry letters 15, 4794-4798 (2005).
[2] steiner aa et al. the hypothermic response to bacterial lipopolysaccharide critically depends on brain cb1, but not cb2 or trpv1, receptors. j physiol. 2011 may 1;589(pt 9):2415-31. |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|